Literature DB >> 14751356

Low AUA symptom score independently predicts positive prostate needle biopsy: results from a racially diverse series of 411 patients.

Christopher R Porter1, Jason Kim.   

Abstract

OBJECTIVES: To evaluate the prebiopsy parameters, including the American Urological Association symptom score (AUASS), that may be predictive of positive biopsy. Transrectal ultrasound (TRUS) biopsy of the prostate represents the reference standard in the diagnosis of prostate cancer.
METHODS: A total of 411 consecutive men undergoing TRUS biopsy were prospectively evaluated. The indications for biopsy were abnormal digital rectal examination (DRE) findings and/or an elevated prostate-specific antigen (PSA) level. A single surgeon (C.R.P.) examined all the men. DRE and TRUS were each given a level of suspicion between 1 (low suspicion--smooth DRE, homogeneous TRUS) and 5 (high suspicion--hard DRE, hypoechoic lesion). A level of suspicion of 3 or greater was considered abnormal. The prebiopsy parameters examined included PSA level, age, race, biopsy history, prostate volume, TRUS-detected lesion, and AUASS.
RESULTS: Of 411 men, 62% were African American and 38% were white. The mean PSA level was 11.6 ng/mL. The mean patient age was 65.3 years. Overall, 39% of men had abnormal DRE and 32% abnormal TRUS findings. The mean AUASS was 9.3. The positive biopsy rate was 40.8%. Univariate analysis demonstrated that age, PSA level, prostate volume, abnormal DRE findings, TRUS-detected lesion, and AUASS (less than 7, low) were all predictive of a positive biopsy (P <0.05). Race was not statistically significant (P = 0.38). Detailed analysis of the AUASS in the 411 men indicated that 41% had low symptom scores (less than 7), 32% had moderate scores (8 to 19), and 27% had severe scores (20 to 35). In the group of men with low symptom scores (n = 169), univariate analysis demonstrated that age, PSA level, prostate volume, and abnormal TRUS findings were all statistically significant predictors of positive biopsy (P <0.05). Multivariate analysis of the data from the 411 men demonstrated that age, PSA level, prostate volume, abnormal DRE findings, and low AUASS were all independent predictors of positive biopsy (P <0.05).
CONCLUSIONS: In this prospective study, the independent predictors of positive TRUS biopsy included age, PSA level, prostate volume, abnormal DRE findings, and low AUASS. A low AUASS may be an important variable to consider when counseling patients before biopsy and when designing patient algorithms for prostate biopsy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751356     DOI: 10.1016/j.urology.2003.08.019

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.

Authors:  Maria Frånlund; Sigrid Carlsson; Johan Stranne; Gunnar Aus; Jonas Hugosson
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

2.  Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Authors:  Amar Bhindi; Bimal Bhindi; Girish S Kulkarni; Robert J Hamilton; Ants Toi; Theodorus H van der Kwast; Andrew Evans; Alexandre R Zlotta; Antonio Finelli; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 3.  Prostatitis and serum prostate-specific antigen.

Authors:  Puneet Sindhwani; Christopher M Wilson
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

4.  Are men who undergo radical prostatectomy with lower urinary tract symptoms at an increased risk for aggressive prostate cancer?

Authors:  Dae Hun Lee; Seung Hwan Lee; Dong Hoon Lee; Mun Su Chung; Byung Ha Chung
Journal:  Korean J Urol       Date:  2011-12-20

5.  Absence of Bladder Outlet Obstruction Is an Independent Risk Factor for Prostate Cancer in Men Undergoing Prostate Biopsy.

Authors:  Luigi Cormio; Giuseppe Lucarelli; Oscar Selvaggio; Giuseppe Di Fino; Vito Mancini; Paolo Massenio; Francesco Troiano; Francesca Sanguedolce; Pantaleo Bufo; Giuseppe Carrieri
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.